Glura 50mg Tablet contains Sitagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the levels of incretin hormones, which increase insulin synthesis and release from pancreatic beta cells in a glucose-dependent manner, while simultaneously decreasing glucagon secretion from alpha cells. This dual action helps to regulate blood glucose levels effectively without causing significant hypoglycemia. Glura 50mg is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. The medication is well-tolerated, with a favorable safety profile, although patients should be monitored for potential adverse effects including nasopharyngitis, headache, and rare instances of pancreatitis. Dose adjustments may be necessary in patients with renal impairment. Glura 50mg Tablet should be taken orally once daily, with or without food, as directed by a healthcare professional. Regular monitoring of blood glucose and renal function is recommended to optimize therapeutic outcomes and minimize risks. This medication is not indicated for type 1 diabetes or diabetic ketoacidosis.

Dosage & How to Use